Saturday 17 October 2026 Export BMRN’s income statement to Excel — free account

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024. In the quarter to June 2026, revenue grew 19.9%, EPS fell 81.6%, free cash flow fell 20.3% and total debt rose 602.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

54.68 1.37 −2.44%

Follow BMRN

Alert me

Market cap: $10.9B
P/E: 144×
Fwd P/E: 16.1×
Dividend yield: —
F-score: 5/9
Altman Z: 5.67
Beneish M: −2.49
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 4.32

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	2	1	—	1	—	—	—	1	—

Insider Ownership 1.21%

Capital & Financial Ratios $m

Market Cap 10,850.00

Revenue 3,406.61

Net Income 72.97

Free Cash Flow 724.81

Net Debt 3,312.14

Current Ratio 2.39

Debt/Equity 0.66

P/E ratio 143.89

Fwd P/E 16.10

P/S ratio 3.10

P/B ratio 1.67

Past 5Y EPS Growth (16.86%)

This Y EPS Growth 179.20%

Next Y EPS Growth 30.25%

Next Y revenue growth 21.29%

Next 5Y EPS Growth 63.31%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 64.96%

10-year low 10-year high

P/S against its own 10 years 0.22%

10-year low 10-year high

P/B against its own 10 years 1.33%

10-year low 10-year high

EV/Sales against its own 10 years 11.50%

10-year low 10-year high

EV/FCF against its own 10 years 15.73%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,074	1,138	1,561	874
Receivables	634	661	908	1,061
Inventory	1,107	1,233	1,299	1,783
Other	141	202	186	254
	2,956	3,232	3,953	3,972

	2023	2024	2025	Q'26
Payables	683	607	759	1,006
ST’ Debt	494	—	—	658
Other	—	—	—	—
	1,177	607	759	1,664

Compound Annual Growth %

	10y	5y	3y
Sales	13.73%	11.60%	15.40%
Cash Flow	0.00%	57.52%	67.59%
Earnings	0.00%	(16.39%)	35.08%
Book Value	9.75%	8.19%	9.76%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	766	990	—	—	—
’25	745	825	776	875	3,221
’24	649	712	746	747	2,854
’23	596	595	581	646	2,419
’22	519	534	505	538	2,096
’21	486	502	409	450	1,846
’20	502	429	477	452	1,860

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	221	168	—	—	—
’25	174	185	369	100	828
’24	47	119	221	186	573
’23	(74)	70	136	27	159
’22	(45)	56	158	7	176
’21	114	83	97	11	305
’20	(15)	28	86	(13)	85

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	200	134	—	—	—
’25	158	168	335	57	717
’24	23	97	200	165	485
’23	(99)	47	112	(9)	52
’22	34	28	122	(36)	148
’21	85	57	77	(33)	185
’20	8	(6)	66	(53)	15

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.54	0.23	—	—	—
’25	0.95	1.23	(0.16)	(0.24)	1.80
’24	0.46	0.55	0.55	0.64	2.21
’23	0.27	0.29	0.21	0.11	0.87
’22	0.63	0.15	(0.04)	0.00	0.75
’21	0.09	0.07	(0.20)	(0.32)	(0.35)
’20	0.44	(0.16)	4.01	0.12	4.53

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	62.12	80.10	75.81	62.88	68.25	71.59	70.73	76.02	61.15	50.76	Analyst estimates 2026–2028 Powerpack
	High	105.61	100.51	106.74	100.13	131.95	92.20	109.56	117.77	99.25	73.51
People
People	Employees	2,293	2,581	2,849	3,001	3,059	3,045	3,082	3,401	3,040	3,221
	Revenue/emp, $m	0.49	0.51	0.52	0.57	0.61	0.61	0.68	0.71	0.94	1.00
Income, $m
Income, $m	Revenue	1,117	1,314	1,491	1,704	1,860	1,846	2,096	2,419	2,854	3,221
	Gross margin, %	81.23	81.59	78.86	78.91	71.82	74.52	76.00	78.01	79.67	77.73
	EBT	(831)	(36)	(143)	(95)	(49)	(75)	150	189	542	482
	EBT margin, %	(74.41)	(2.73)	(9.57)	(5.56)	(2.63)	(4.08)	7.14	7.79	18.98	14.98
	Net income	(630)	(117)	(77)	(24)	854	(64)	142	168	427	349
	Depreciation	98	91	96	103	106	113	105	95	88	75
Per share, $
Per share, $	Revenue	6.73	7.53	8.42	9.52	10.29	10.10	11.31	12.88	15.02	16.80
	Earnings	(3.80)	(0.67)	(0.44)	(0.13)	4.75	(0.35)	0.76	0.89	2.25	1.82
	Cash flow	(1.37)	(0.05)	0.11	0.27	0.47	1.67	0.95	0.85	3.01	4.32
	Capex	(0.89)	(0.43)	(0.53)	(0.77)	(0.39)	(0.65)	(0.15)	(0.57)	(0.46)	(0.58)
	Free cash flow	(2.27)	(0.48)	(0.42)	(0.50)	0.08	1.01	0.80	0.28	2.55	3.74
	Book value	16.67	16.10	16.76	17.44	22.71	23.33	24.85	26.36	29.77	31.74
	Shares, m	166	174	177	179	181	183	185	188	190	192
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	18.58	0.00	130.66	110.17	29.21	32.65
	P/S	12.76	12.09	10.11	8.88	8.52	8.75	8.89	7.61	4.38	3.54
	P/B	5.15	5.65	5.08	4.85	3.86	3.79	4.05	3.72	2.21	1.87
	EV/Sales	12.66	11.92	10.19	8.94	8.53	8.79	8.80	7.62	4.36	3.39
	EV/FCF	(40.24)	687.66	300.41	(168.97)	1,058.08	87.58	124.87	356.84	25.63	15.24
Cash, $m
Cash, $m	Operating cash flow	(228)	(9)	20	48	85	305	176	159	573	828
	Capex	(148)	(74)	(95)	(138)	(70)	(119)	(28)	(108)	(87)	(111)
	Free cash flow	(376)	(83)	(74)	(90)	15	185	148	52	485	717
Balance, $m
Balance, $m	Working capital	982	1,391	1,533	1,010	1,850	1,728	2,163	1,779	2,625	3,194
	Total debt	683	1,174	830	848	1,087	1,089	1,093	1,087	595	597
	Net debt	(106)	(221)	(254)	94	22	75	(199)	13	(543)	(963)
	Shareholders’ equity	2,766	2,809	2,968	3,122	4,106	4,266	4,603	4,952	5,658	6,087
Returns, %
Returns, %	ROA	(16.26)	(2.70)	(1.70)	(0.52)	16.21	(1.08)	2.29	2.54	6.17	4.79
	ROIC	(18.88)	(0.36)	(2.84)	(1.95)	(0.66)	(1.19)	2.28	2.34	5.92	5.00
	ROE	(24.39)	(4.20)	(2.67)	(0.78)	23.63	(1.53)	3.19	3.51	8.05	5.94

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CORT Corcept Therapeutics Incorporated	$12.3B	212×	139×	+31.74% (above 0%: growing)	+21.21% (above 0%: growing)	−29.89% (below 0%: shrinking)	98.41%	16.12%	Compare
SMMT Summit Therapeutics PLC	$12.3B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−112.80% (below 0%: shrinking)	0.00%	0.00%	Compare
TECH Bio-Techne Corp	$11.4B	62.0×	37.6×	+1.33% (above 0%: growing)	n/m	−6.83% (below 0%: shrinking)	65.82%	23.13%	Compare
BMRN BioMarin Pharmaceutical Inc.	$10.9B	144×	16.1×	+19.91% (above 0%: growing)	−81.60% (below 0%: shrinking)	−20.28% (below 0%: shrinking)	79.51%	11.21%
MDGL Madrigal Pharmaceuticals, Inc.	$10.6B	— (loss-making)	— (loss-making)	+71.17% (above 0%: growing)	n/m	+140.54% (above 0%: growing)	89.02%	(15.46%)	Compare
IBRX ImmunityBio, Inc.	$10.6B	— (loss-making)	— (loss-making)	+93.91% (above 0%: growing)	n/m	+13.38% (above 0%: growing)	99.42%	(120.41%)	Compare
PCVX Vaxcyte, Inc.	$10.3B	— (loss-making)	—	—	n/m	−92.55% (below 0%: shrinking)	0.00%	0.00%	Compare
KRYS Krystal Biotech, Inc.	$9.8B	38.3×	38.6×	+24.14% (above 0%: growing)	+39.10% (above 0%: growing)	+40.14% (above 0%: growing)	94.60%	49.00%	Compare
KYMR Kymera Therapeutics, Inc.	$9.0B	— (loss-making)	— (loss-making)	+466.40% (above 0%: growing)	n/m	+9.97% (above 0%: growing)	100.00%	(116.32%)	Compare
Median of peers	$10.6B	62.0×	38.6×	+31.74%	—	+1.57%	91.81%	0.00%

All 614 Biotechnology stocks →

BioMarin Pharmaceutical Inc. (BMRN) key facts

Strength: BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
BioMarin Pharmaceutical Inc. (BMRN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BMRN traded at $54.68, a market capitalization of $10.9 billion.
Return on equity was 5.94% and debt-to-equity 0.66.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 5.67 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.